Global Information
회사소개 | 문의 | 비교리스트

경구 약물전달 : 시장 예측(2022-2027년)

Oral Drug Delivery Market - Forecasts from 2022 to 2027

리서치사 Knowledge Sourcing Intelligence
발행일 2022년 04월 상품코드 1086983
페이지 정보 영문 111 Pages 배송안내 1-2일 (영업일 기준)
가격
US $ 3,950 ₩ 5,611,000 PDF (Single User License)
US $ 4,550 ₩ 6,463,000 PDF (Multiple User License)
US $ 6,950 ₩ 9,873,000 PDF (Enterprise License)


경구 약물전달 : 시장 예측(2022-2027년) Oral Drug Delivery Market - Forecasts from 2022 to 2027
발행일 : 2022년 04월 페이지 정보 : 영문 111 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 경구 약물전달 시장 규모는 2020년에 983억 200만 달러로 평가되었으며, 예측 기간에 6.04%의 연평균 복합 성장률(CAGR)로 성장을 지속하여 2027년까지 1,482억 100만 달러에 달할 것으로 예측됩니다.

경구 약물전달은 비침습적이고, 환자 컴플라이언스 비율이 높으며, 취급이 용이하고, 특별한 무균 상태를 필요로 하지 않기 때문에 가장 일반적인 투여 방법으로 여겨지고 있습니다.그 때문에 폭넓은 층이 소비자에게 선호되고 있습니다. 예측 기간에는 시장 진출기업간의 협력 관계, 만성질환 발생률 상승, 세계 고령자 인구 증가 등 다양한 요인이 시장 성장에 박차를 가할 것으로 예상됩니다.

세계의 경구 약물전달(Oral Drug Delivery ) 시장을 조사했으며, 시장 규모와 예측, 시장 성장 촉진요인 및 과제, 시장 동향, 제제별·용도별·지역별 시장 분석, 경쟁 구도, 주요 기업 프로파일 등의 정보를 제공합니다.

목차

제1장 서론

  • 시장의 정의
  • 시장 세분화

제2장 조사 방법

  • 조사 데이터
  • 전제조건

제3장 개요

  • 조사 하이라이트

제4장 시장 역학

  • 성장 촉진요인
  • 성장 억제요인
  • Porter의 산업 분석
    • 공급 기업의 교섭력
    • 바이어의 교섭력
    • 대체품의 위협
    • 신규 진출업체의 위협
    • 경쟁 기업간 경쟁 관계
  • 업계 밸류체인 분석

제5장 경구 약물전달 시장 : 제제별

  • 서론
  • 정제
  • 캡슐
  • 드롭
  • 분말
  • 액체/시럽
  • 탕약

제6장 경구 약물전달 시장 : 용도별

  • 서론
  • 질병 치료
  • 연구/학술 목적

제7장 경구 약물전달 시장 : 지역별

  • 서론
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 남미
    • 브라질
    • 아르헨티나
    • 기타
  • 유럽
    • 독일
    • 프랑스
    • 영국
    • 스페인
    • 기타
  • 중동 및 아프리카
    • 사우디아라비아
    • 이스라엘
    • 기타
  • 아시아태평양
    • 중국
    • 일본
    • 한국
    • 인도
    • 태국
    • 한국
    • 대만
    • 인도네시아
    • 기타

제8장 경쟁 환경과 분석

  • 주요 기업과 전략 분석
  • 신규 기업과 시장 수익성
  • 합병/인수/합의/협업
  • 벤더의 경쟁력 매트릭스

제9장 기업 개요

  • Pfizer Inc.
  • AstraZeneca
  • Alpex Pharma S.A.
  • SPI Pharma
  • Globela Pharma Pvt Ltd
  • Lupin Pharmaceuticals, Inc.
  • Mayne Pharma Group Limited
  • Adare Pharmaceuticals, Inc.
  • AdhexPharma
  • Aquestive Therapeutics
LSH 22.06.17

The oral drug delivery market is expected to grow at a CAGR of 6.04% during the forecast period to reach US$148.201 billion by 2027, from US$98.302 billion in 2020. Because oral drug delivery is noninvasive, has a high rate of patient compliance, is easy to handle, and does not require any special sterile conditions, it is considered the most popular method of administration. Hence, it is highly preferred by a wide spectrum of consumers. Because of the prevalence of chronic diseases around the world, these are in high demand. Moreover, rising research and development investment, advancing health expenditure, and an ageing population will all contribute to market expansion throughout the projection period. The oral drug delivery market can be segmented by formulation, application, and geography.

Various factors are expected to drive the oral drug delivery market during the forecast period, including an increase in the number of collaborations among market participants, an increase in the incidence of chronic diseases, and an increase in the global geriatric population.

People are embracing a more sedentary lifestyle as the middle class expands and urbanisation accelerates. Obesity rates and occurrences of diseases like diabetes are rising as a result of this. According to the World Health Organization, the prevalence of chronic disease will rise by 57% by 2020. GlobalData epidemiologists predict that by 2021, India will have 75.26 million diagnosed prevalent cases of type 2 diabetes and 26,000 diagnosed incident cases of endometrial cancer, with 91.72 million and 32,000 cases, respectively, by 2028. According to the American Cancer Society, in 2021, there will be 1.9 million new cancer diagnoses and 608,570 cancer deaths in the United States. According to a report published by Frontiers In Public Health, chronic noncommunicable diseases account for about 80% of the mortality among adults aged 60 in China, with ischemic heart disease, stroke, chronic obstructive pulmonary disease (COPD), and type 2 diabetes being the most common. Smoking, alcohol usage, sedentary activity, and poor nutritional intake are all significant contributors to these diseases. Oral drug delivery systems are expected to become more popular as the prevalence of chronic diseases rises around the world.

According to the World Population Prospects: the 2019 Revision, by 2050, one out of every six people on the planet will be over the age of 65 (16%), from one out of every eleven in 2019 (9%). One in every four people in Europe and North America could be 65 or older by 2050. In 2018, people aged 65 and older outnumbered kids under the age of five for the first time in history on a global level. From 143 million in 2019 to 426 million in 2050, the number of people aged 80 and up is expected to treble. Eastern and South-Eastern Asia's population aged 65 and above nearly doubled from 6% in 1990 to 11% in 2019, while Latin America and the Caribbean's population aged 65 and above nearly doubled from 5% in 1990 to 9% in 2019. The growing geriatric population around the world is also expected to propel market growth in the forecast period.

Moreover, rising research and development and partnerships amongst market players will expand the growth of oral delivery globally. For instance, SWK Holdings Corporation announced the acquisition of Enteris BioPharma in August 2019. This acquisition will allow the company to broaden its product line and provide more advanced products to its clients. This will also allow the company to become a pioneer in the field of orally delivered peptide and small molecule therapies. Similarly, in September 2021, Bio-Thera Solutions signed an agreement with Intract, acquiring the licence to employ the oral delivery system with a single monoclonal antibody that will remain unnamed. Moreover, in November 2021, EsoCap completed private funding round, with existing and new investors participating. The funds will be utilised to further develop and industrialise EsoCap's focused application technology, which will allow for the effective local therapy of esophageal illnesses.

During the projected period, North America is anticipated to dominate the oral drug delivery market.

During the forecast period, North America is expected to have a large market share. Technological advances, rising patent approvals, and research on the usage of nanotechnology for drug delivery in the region are expected to drive the market. For example, Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical firm researching oral drug delivery systems, got a US patent in March 2019. Furthermore, due to the rapid adoption of new drug delivery technologies and the presence of research centres developing innovative drug delivery systems in the country, the United States is expected to hold a significant share of the oral drug delivery systems market in North America during the forecast period.

COVID -19 Insights

The COVID-19 pandemic has had a positive impact on the market for oral drug delivery because the demand for healthcare has increased exponentially around the world as a result of the virus outbreak. Since the disease's emergence, finding effective medications to treat COVID-19 has been a top priority. For instance, Merck and Ridgeback collaborated on the development of Molnupiravir, an oral antiviral medication. The drug delivery market has grown as a result of a lack of appropriate treatment, healthcare infrastructure, and medicine unavailability. Furthermore, as a result of the pandemic, the FDA clearance process became relatively easier, resulting in increased market growth.

Market Segmentation:

  • By Formulation

Tablets

Capsules

Drops

Powder

Liquid or Syrup

Decoction

  • By Application

Disease Treatment

Research/Academic purposes

  • By Geography

North America

  • USA
  • Canada
  • Mexico

South America

  • Brazil
  • Argentina
  • Others

Europe

  • Germany
  • France
  • United Kingdom
  • Spain
  • Others

Middle East and Africa

  • Saudi Arabia
  • Israel
  • Others

Asia Pacific

  • China
  • Japan
  • South Korea
  • India
  • Thailand
  • South Korea
  • Taiwan
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Powers of Buyers
    • 4.3.3. Threat of Substitutes
    • 4.3.4. Threat of New Entrants
    • 4.3.5. Competitive Rivalry in Industry
  • 4.4. Industry Value Chain Analysis

5. ORAL DRUG DELIVERY MARKET, BY FORMULATION 

  • 5.1. Introduction
  • 5.2. Tablets
  • 5.3. Capsules
  • 5.4. Drops
  • 5.5. Powder
  • 5.6. Liquid or Syrup
  • 5.7. Decoction

6. ORAL DRUG DELIVERY MARKET, BY APPLICATION

  • 6.1. Introduction
  • 6.2. Disease Treatment
  • 6.3. Research/Academic purposes

7. ORAL DRUG DELIVERY MARKET, BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. United States
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. United Kingdom
    • 7.4.4. Spain
    • 7.4.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. Israel
    • 7.5.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. Japan
    • 7.6.3. South Korea
    • 7.6.4. India
    • 7.6.5. Thailand 
    • 7.6.6. South Korea
    • 7.6.7. Taiwan 
    • 7.6.8. Indonesia
    • 7.6.9. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrativeness
  • 8.3. Mergers, Acquisition, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES

  • 9.1. Pfizer Inc.
  • 9.2. AstraZeneca
  • 9.3. Alpex Pharma S.A.
  • 9.4. SPI Pharma
  • 9.5. Globela Pharma Pvt Ltd
  • 9.6. Lupin Pharmaceuticals, Inc.
  • 9.7. Mayne Pharma Group Limited
  • 9.8. Adare Pharmaceuticals, Inc.
  • 9.9. AdhexPharma
  • 9.10. Aquestive Therapeutics
Back to Top
전화 문의
F A Q